NCT03993964: Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must be HER2+ & received at least 1 line of therapy in the metastatic setting
Exclusions: Patients with symptomatic brain metastasis; Patients with prior treatment of tyrosine-kinase inhibitors targeting HER2 (neratinib, lapatinib, pyrotinib, etc.)

Comments are closed.

Up ↑